Grant: Engage Grants Program
McGill University
$25,000.00
Biomedical applications of cold plasma generated reactive oxygen species
FY 2013-14
Summary
Reactive oxygen species (ROS) are known to attack bioactive molecules like DNA, proteins and somecomponents of cell membranes. If the production of ROS can be controlled then it might be possible to useROS to selectively damage or even repair components of cells, for example, in applications associated withcancer therapies. This project intends to assist Canadian company, NexPlasmaGen, in quantifying andcharacterizing ROS produced by a cold plasma applicator developed by the company. The company seeks toidentify and determine the concentration of hydroxyl radical and superoxide anion in aqueous solution asfunctions of variations in the plasma applicator parameters like power, duty cycle, etc. The ROS that aregenerated by the applicator can be detected by electron paramagnetic resonance (EPR). This is a very sensitivespectroscopic technique that is selective for radical species. EPR instruments are sophisticated tools that usecombinations of high magnetic fields and microwave energy to detect radicals. Such instruments are rare inCanada, so NexPlasmaGen has approached McGill University with its EPR facility to carry out this research. Inthe past, Andrews (McGill) has provided his EPR expertise in collaborations with medical researchers to studyROS production in the context of iron chelating agents to treat iron-loading anemias. His experience in theEPR of ROS is thus relevant to the needs of NexPlasmaGen. Moreover, Andrews brings his experience withhis own development stage companies to the research project with NexPlasmaGen. He understands theconstraints and timelines under which they operate, and this experience is of value to NexPlasmaGen.The ROS produced by the plasma applicator are generally transient, so spin trapping will be used to convert theunstable ROS into more stable compounds that can be observed and quantified by EPR. NexPlasmaGen needsthese data to understand and validate the clinical potential of its plasma applicator for potential use in medicalapplications like the manipulation of cells, surface functionalization, polymer deposition, enhanced cellpermeation and treatment of cancer.
Program
Engage Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
453395-2013
Name nom
Andrews, Mark
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3403
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Spectroscopy
Research subject fr
Spectroscopie
Partie
1
Nb partie
1
Application title
Biomedical applications of cold plasma generated reactive oxygen species
Keyword
NSERC
Application summary
Reactive oxygen species (ROS) are known to attack bioactive molecules like DNA, proteins and somecomponents of cell membranes. If the production of ROS can be controlled then it might be possible to useROS to selectively damage or even repair components of cells, for example, in applications associated withcancer therapies. This project intends to assist Canadian company, NexPlasmaGen, in quantifying andcharacterizing ROS produced by a cold plasma applicator developed by the company. The company seeks toidentify and determine the concentration of hydroxyl radical and superoxide anion in aqueous solution asfunctions of variations in the plasma applicator parameters like power, duty cycle, etc. The ROS that aregenerated by the applicator can be detected by electron paramagnetic resonance (EPR). This is a very sensitivespectroscopic technique that is selective for radical species. EPR instruments are sophisticated tools that usecombinations of high magnetic fields and microwave energy to detect radicals. Such instruments are rare inCanada, so NexPlasmaGen has approached McGill University with its EPR facility to carry out this research. Inthe past, Andrews (McGill) has provided his EPR expertise in collaborations with medical researchers to studyROS production in the context of iron chelating agents to treat iron-loading anemias. His experience in theEPR of ROS is thus relevant to the needs of NexPlasmaGen. Moreover, Andrews brings his experience withhis own development stage companies to the research project with NexPlasmaGen. He understands theconstraints and timelines under which they operate, and this experience is of value to NexPlasmaGen.The ROS produced by the plasma applicator are generally transient, so spin trapping will be used to convert theunstable ROS into more stable compounds that can be observed and quantified by EPR. NexPlasmaGen needsthese data to understand and validate the clinical potential of its plasma applicator for potential use in medicalapplications like the manipulation of cells, surface functionalization, polymer deposition, enhanced cellpermeation and treatment of cancer.